279 Metabolic Syndrome (MetS) in elderly with heart failure: how much does it really matter? - Clinical aspects, practical involvements

2007 ◽  
Vol 6 (1) ◽  
pp. 58-58
Author(s):  
D TOPORAN ◽  
C TANASEANU ◽  
M VINTILA
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Clinical Aspects

Abstract 12777: High Sensitivity Troponin T is Associated With Increased Heart Failure Risk in Metabolic Syndrome in the Atherosclerosis Risk in Communities (ARIC) Study

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Yashashwi Pokharel ◽  
Wensheng Sun ◽  
Dennis Villarael ◽  
Elizabeth Selvin ◽  
Salim Virani ◽  
...  
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Myocardial Injury ◽  
Troponin T ◽  
Cox Model ◽  
High Sensitivity ◽  
Cvd Risk ◽  
Chi Square ◽  
High Sensitivity Troponin ◽  
High Sensitivity Troponin T

Background: Metabolic syndrome (MS) is associated with higher CVD risk. High sensitivity troponin T (hsTnT) is a marker of myocardial injury and an emerging marker for heart failure (HF) risk prediction. We examined whether hsTnT is associated with increased HF risk in people with similar number of MS components present at baseline in 10316 ARIC participants without prevalent HF. Methods: We used Wald Chi-square test to assess the interaction between MS and hsTnT and Cox model for the association of incident HF hospitalization by hsTnT categories across groups created by the number of MS components after adjusting for risk factors and NT-proBNP (Table). Results: The mean age of the study population was 63 (SD, 6) years (56% women). Mean hsTnT levels were higher with increasing MS components (Table). There were 1353 HF hospitalizations over a median of 14 years. The interaction of MS with hsTnT for HF was borderline significant (p-interaction 0.059). Compared to individuals without MS and hsTnT<5 ng/L the HRs (95%CIs) were 1.7 (1.4-2.1) in those without MS and hsTnT≥5 ng/L; 1.7 (1.3-2.1) in MS and hsTnT<5 ng/L; and 3.6 (3.0-4.4) in MS and hsTnT≥5 ng/L. In groups with 1-5 MS components present, increasing hsTnT was significantly associated with higher hazards for HF in each group with the highest HR in those with all 5 MS components (Table). Conclusion: Presence of higher MS risk components was associated with increasing subclinical myocardial injury as assessed by higher hsTnT. The hazards for HF were numerically similar in individuals without MS but detectable hsTnT (>5 ng/L) as to those with MS but undetectable hsTnT. In people with similar number of MS components higher hsTnT levels were associated with increased HF hazards suggesting that in MS hsTnT could be a useful marker for identifying those at higher risk for incident HF.

Metabolic Syndrome and Adipose Tissue: New Clinical Aspects and Therapeutic Targets

2007 ◽  
Vol 13 (21) ◽  
pp. 2148-2168 ◽  
Author(s):  
C.V. Iannucci ◽  
D. Capoccia ◽  
M. Calabria ◽  
F. Leonetti
Keyword(s):  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Therapeutic Targets ◽  
Clinical Aspects

scholarly journals Metabolic syndrome and heart failure: mechanism and management

2021 ◽  
Author(s):  
Sidhi Laksono Purwowiyoto ◽  
Ananta Siddhi Prawara
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
World Population ◽  
Neurohormonal Activation ◽  
Comprehensive Management ◽  
The World ◽  
Current Guidelines ◽  
Careful Management

Heart failure (HF) and metabolic syndrome (MetS) are syndromes that affect a large proportion of the world population. MetS is known to be one of the risk factors of HF, and it can also act as comorbidity in HF. This review aims to further discuss the mechanism of MetS in causing HF, the management of MetS in order to prevent HF, and the management of MetS in HF patients. Visceral adiposity is the primary trigger of MetS which is followed by chronic inflammation, insulin resistance, and neurohormonal activation. All the mechanisms causing MetS play also an important role in the progression of HF. The MetS approach can be achieved by managing its components according to the current guidelines and careful management of MetS should be done in patients with HF. MetS is closely related to the progression of HF so that comprehensive management which involves a multidisciplinary team is necessary for managing patients with metabolic syndrome and heart failure.

scholarly journals Influence of metabolic syndrome and gender on heart failure following acute coronary syndrome

2014 ◽  
Vol 9 (9-10) ◽  
pp. 344-345
Author(s):  
Darko Kranjcec ◽  
Mijo Bergovec ◽  
Miroslav Raguz
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Acute Coronary Syndrome ◽  
Coronary Syndrome ◽  
And Gender

scholarly journals Prognostic Impact of Metabolic Syndrome in Patients With Heart Failure: A Meta-Analysis of Observational Studies

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhuo-Ming Huang ◽  
Wen-Rong Chen ◽  
Qi-Wen Su ◽  
Zhuo-Wen Huang
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Cardiovascular Mortality ◽  
Cardiovascular Events ◽  
Observational Studies ◽  
Meta Analysis ◽  
Prognostic Impact ◽  
The Metabolic Syndrome ◽  
All Cause Mortality ◽  
The Impact

Background: The metabolic syndrome (MS) is significantly associated with the risk of incident heart failure (HF). However, there are still great controversies about the impact of MS on the prognosis in patients with established HF. This meta-analysis aimed to ascertain the effect of MS on the prognosis in patients with HF.Methods: We searched multiple electronic databases, including PubMed, Opengrey, EMBASE, and Cochran Library, for potential studies up to February 15, 2021. Observational studies that reported the impact of MS on the prognosis in patients with established HF were included for meta-analysis.Results: Ten studies comprising 18,590 patients with HF were included for meta-analysis. The median follow-up duration of the included studies was 2.4 years. Compared with HF patients without MS, the risk of all-cause mortality and cardiovascular mortality was not increased in HF with MS (HR = 1.04, 95% CI = 0.88–1.23 for all-cause mortality; HR = 1.66, 95% CI = 0.56–4.88 for cardiovascular mortality, respectively). However, there was a significant increase in composited cardiovascular events in the HF patients with MS compared with those without MS (HR = 1.73, 95% CI = 1.23–2.45).Conclusions: In patients with established HF, the presence of MS did not show an association on the risk of all-cause mortality or cardiovascular mortality, while it may increase the risk of composite cardiovascular events.

Sign in / Sign up

Export Citation Format

Share Document